Navigation Links
Eigen Receives Two Grant Awards from U.S. Department of Health & Human Services

GRASS VALLEY, Calif., April 22, 2011 /PRNewswire/ -- Eigen is the proud recipient of two grant awards from the Qualifying Therapeutic Discovery Project (QTDP) funded by the U.S. Department of Health & Human Services. QTDP tax credits are provided under section 48D of the Internal Revenue Code (IRC), enacted as part of the Patient Protection and Affordable Care Act of 2010 (P.L. 111-148). Eigen received the maximum $244,000 award for each grant awarded in October, 2010, and January, 2011. These credits support biomedical research by small companies which may have major impact on the diagnosis and treatment of significant diseases.  

With this grant, Eigen continues to rapidly move forward, bringing breakthrough medical imaging products to market. Additionally, the QTDP grants have enabled the company to hire additional local talent to support growing company needs.  

Artemis, Eigen's flagship product, uses proprietary, next-generation imaging technology and provides solutions—not previously available—which enhance urologists' existing 2D ultrasound imagery with full color 3D modeling used for "smart" prostate biopsies.

"Artemis has provided a great leap forward in the diagnosis of prostate cancer," says Brian Burr, Eigen CEO. "It has added precision along with the ability to guide, track, and record exact biopsy locations. Artemis lets doctors re-biopsy the same location accurately in a subsequent biopsy. This has previously not been an option. Artemis technology provides high quality, real-time information that enhances how prostate cancer is managed. Better patient information equals better patient decisions."

Eigen is also breaking into the prostate cancer therapy market.  The company hopes to receive future support from such programs as the QTDP, allowing it to continue providing quality imaging devices to medical professionals worldwide.

About Eigen

Eigen is a world leader in the development of innovative imaging devices and technology that lets healthcare professionals improve their ability to visualize, diagnose and determine appropriate treatment pathways in over 4,000 hospitals worldwide. Located at 13366 Grass Valley Avenue, Grass Valley, CA  95945, visit Eigen at

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Morphotek Receives Grant to Support Development of Therapeutic Antibodies against Biowarfare Agents
2. MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
3. Morphotek®, Inc. Receives Beacon Award From CancerCare
4. Cellectis Receives Payment for License to Homologous Recombination Patents
5. China-Biotics Receives First U.S. Sales Order
6. BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens
7. Teysuno™ (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
8. ACT Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for hESC-Derived RPE Cells for Treatment of Stargardts Disease
9. Mylans Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg
10. Everist Genomics Laboratory Receives Approval From U.S. Regulatory Authorities For High Complexity Clinical Testing
11. EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
Post Your Comments:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: ... area for financial services, but it also plays a fundamental ...
Breaking Biology News(10 mins):